Detailseite
Projekt Druckansicht

CO-releasing molecules (CORMs) als Wirkstoffe zur Förderung der Wundheilung

Fachliche Zuordnung Pharmazie
Förderung Förderung von 2015 bis 2020
Projektkennung Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 284059745
 
Erstellungsjahr 2020

Zusammenfassung der Projektergebnisse

Carbon monoxide is now well-recognized as an important small signalling mediator in the human body. In addition to its endgenous enzymatic production from heme by heme oxygenase (HO), there is also considerable biomedical interest in metal carbonyl complexes and other carrier compounds as CO-releasing molecules (CORMs). Inspired by the finely tuned balance between cytoprotective and cytotoxic activity, CORMs are now studied for a range of therapeutic applications. Based on the recognition of the role of HO in wound healing and the ease of topical application of CORM prodrugs in combination with photoactivation, the aim of this project was to explore novel CO releasing molecules conjugated to cellular targeting vectors, contrast these molecular systems with CO-loaded nanomaterials, and study their biological activity in the promotion of wound healing. Based on a generalized synthetic approach, both the "CO-release sphere" and the "drug sphere" of manganese tricarbonyl-based CORMs were widely modified and the CO carrier moiety attached to a range of targeting vectors aimed at cellular membranes, nuclear DNA, and the mitocondria. In addition, Re congeners of the Mn title compounds were also prepared and showed promising properties for intracellular tracking using fluorescence microscopy. Immobilization of metal carbonyl complexes in the inner pores of metal-organic frameworks (MOFs) lead to significantly higher loading than surface functionalization demonstrated in previous works, but the characterization and further optimization of these CORM nanomaterials was hampered by relocation of a key collaborator. Still, promising biological activity was demonstrated for selected new CORMs, including significant antibacterial potency on clinical isolates of pathogenic bacterial strains, which are also relevant in the context of wound infections. One of the title compounds turned out to be non-toxic even at very high concentration and showed significant bacterial clearance in two in vivo model systems. In particular, in initial animal experiments with chicken infected with Avian pathogenic E. coli, a significant reduction in bacterial load by at least one order of magnitude was observed after single dose oral treatment with the lead compound at 20 mg/kg, demonstrating the promise of metal complexes in biomedical applications. In particular, the non-toxicity of the manganese carbonyl compounds at 80 mg/kg (equivalent to 6 g for a 75 kg human) defies the general opinion that metal complexes are generally toxic and therefore unsuitable for drug development. In summary, in this project, the scope of CO-releasing molecules (CORMs) has been significantly expanded to feature a wide range of biological carrier systems, which will help to elucidate the primary cellular structures relevant for CO bioactivity. The challenge is now to orchestrate the various further biological assays under way and further advance the main lead compound to applications e.g. in animal health.

Projektbezogene Publikationen (Auswahl)

 
 

Zusatzinformationen

Textvergrößerung und Kontrastanpassung